Division of Sanofi
Latest From Chattem Inc.
Council of Better Business Bureaus' advertising review appeals panel says Sanofi didn't support claiming ACT Dry Mouth Lozenges "are uniquely formulated to stimulate saliva flow” because no evidence supported uniqueness. On review of initial findings from August 2018 on GSK challenge, which markets Biotene dry mouth products, panel considered appeals by both firms.
National Advertising Division recommends Sanofi add "nearly" to claim that Xyzal Allergy 24HR is "as effective at half the size" of J&J's Zyrtec in a TV ad because 3D modeling comparing the products showed Xyzal tablet has 73-mm volume and a Zyrtec tablet's is 145.2 mm. Sanofi's evidence also supported referring to Xyzal's size would not mislead consumers to expect its drug has half the pharmaceutical dosage of Zyrtec.
Sanofi and GSK appeal Council of Better Business Bureaus investigative arm's recommendations from review of ACT Dry Mouth ad claims. GSK disagrees that Sanofi's could continue using a claim of "moisturizes dry mouth" and Sanofi disagrees that it did not substantiate claims that established ACT Dry Mouth, marketed with cavity prevention claims, as providing benefits similar to GSK's Biodene, which has pre-market approval for an indication of lubricating and coating the interior of the mouth and gums with moisture.
Biodene maker GSK challenged Sanofi's ACT Dry Mouth advertising and both companies find disappointments in the Better Business Bureaus' advertising division's review.
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: (615) 821-4571
1715 West 38th St.
P.O. Box 2219 Chattanooga, TN 37409
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.